Chronic COVID-19 infection in an immunosuppressed patient shows changes in lineage over time: a case report

Table 1 Approximate times of sampling for various COVID-19 lineages, as well as symptoms and disease status and treatment at these timepoints

Approximate time	COVID lineage	Symptoms/disease	Treatment
2019	None	Hodgkin’s Lymphoma	ABVD chemotherapy followed by GDP chemotherapy and autologous stem cell transplant
February 2021	None	Hodgkin’s Lymphoma disease progression, Graft versus host disease	Allogenic stem cell transplant, prednisome
March 2021	B.1.1.176	Mild upper respiratory tract infection, Epstein–Barr viral reactivation	Bamlanivimab
April 2021	B.1.1.176	Post-transplant lymphoproliferative disorder	Rituximab
June 2021	B.1.1.176
June 2021	B.1.1.176
July 2021	B.1.1.176	Progressive cough and shortness of breath	Remdesivir, dexamethasone, Bamlanivimab
July 2021	B.1.1.176
July 2021	B.1.1.176
August 2021	B.1.1.176
January 2022	Not determined	Hospitalized with shortness of breath and bilateral lung consolidations	Sotrovimab, remdesivir, dexamethasone
May 2022	B.1.1.176/BA.1
June 2022	BA.2.9
June 2022	BA.2.9
June 2022		Death

ISSN: 1743-422X